Treatment of Mycobacteriosis with Lung Destruction Using Long-Term Endobronchial Valve Implantation
https://doi.org/10.21292/2075-1230-2022-100-1-49-54
Abstract
The article describes a case of effective treatment of fibrous cavernous pulmonary mycobacteriosis with the implantation of the endobronchial valve (valve bronchial block).
Subjects and Methods. A 66-year-old man was diagnosed with fibrous cavernous pulmonary mycobacteriosis. M. chelonae was detected as a causative agent of the disease. At the time of diagnosis, the disease lasted for 12 months, the duration of treatment due to the erroneous diagnosis of tuberculosis made 6.5 months, the drug therapy of mycobacteriosis lasted for 11 months, and after development of the adverse event in the form of constant tinnitus, the patient interrupted the drug therapy. The patient received no drug therapy for 24 months before the implantation of the endobronchial valve.
Result. The cure of mycobacteriosis and cavity healing were achieved after the implantation of the endobronchial valve. The endobronchial valve remained in the bronchus for 22 months. During this period and after the removal of the endobronchial valve, the patient did not take any medications, lived an active life and was managed on an outpatient basis.
About the Authors
O. V. Lovacheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Olga V. Lovacheva - Doctor of Medical Sciences, Professor, Chief Researcher of Department for Differential Diagnostics and Treatment of Tuberculosis and Concurrent Infections
Build. 2, 4, Dostoevskiy St., Moscow, 127473
А. E. Russkikh
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Anastasia E. Russkikh - Researcher of Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections, Endoscopist
Build. 2, 4, Dostoevskiy St., Moscow, 127473
А. N. Gracheva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Aleksandra N. Gracheva - Bacteriologist of Microbiological Laboratory
Build. 2, 4, Dostoevskiy St., Moscow, 127473
А. E. Panova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Anna E. Panova - Candidate of Medical Sciences, Head of Microbiological Research Laboratory
Build. 2, 4, Dostoevskiy St., Moscow, 127473
А. G. Samoylova
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Anastasia G. Samoylova - Doctor of Medical Sciences, Deputy Director for Research
Phone: +7 (495) 681-07-46
Build. 2, 4, Dostoevskiy St., Moscow, 127473
I. А. Vasilyeva
National Medical Research Center of Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Irina A. Vasilyeva - Doctor of Medical Sciences, Professor, Director
Phone: +7 (495) 681-11-66
Build. 2, 4, Dostoevskiy St., Moscow, 127473
References
1. Lyamin А.V., Ismatullin D.D., Zhestkov А.V., Kovalev А.M., Baryshnikova L.А., Nenyajkin S.S. The comparative analysis of methods for identification of non-tuberculous mycobacteria isolated from clinical specimens. Infektsiya I Immunitet, 2017, vol. 7, no. 3, pp. 285-291. (In Russ.)
2. Griffith D.E., Aksamit T., Brown-Elliott B.A. et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med., 2007, no. 175, pp. 367-416.
3. Haworth C.S., Banks J., Capstick T. et al. British Thoracic Society Guideline for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). BMJ Open Resp. Res., 2017, no. 4, e000242. doi:10.1136/bmjresp-2017-000242.
4. Kang H.K., Park H.Y., Kim D. et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect. Dis., 2015, no. 15, pp. 7.
5. Philley J.V., DeGroote M.A., Honda J.R., Chan M.M., Kasperbauer S., Walter N.D., Chan E.D. Treatment of non-tuberculous mycobacterial lung disease. Curr. Treat. Options Infect. Dis., 2016, vol. 8, no. 4, pp. 275-296. doi:10.1007/s40506-016-0086-4.
6. Russkikh A., Gracheva A., Lovacheva O., Vasilyeva I. Endobronchial valve treatment for cavitary pulmonary diseases caused by non-tuberculosis mycobacteria. Eur. Respir. J. Supplement, 2019, vol. 54, no. S63, PA4586.
Review
For citations:
Lovacheva O.V., Russkikh А.E., Gracheva А.N., Panova А.E., Samoylova А.G., Vasilyeva I.А. Treatment of Mycobacteriosis with Lung Destruction Using Long-Term Endobronchial Valve Implantation. Tuberculosis and Lung Diseases. 2022;100(1):49-54. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-1-49-54
Views:
668
Email this article 